Appointment of Joint Broker

RNS Number : 0581S
Accrol Group Holdings PLC
07 March 2023
 

7 March 2023

 

Accrol Group Holdings plc

("Accrol", the "Group" or the "Company")

 

APPOINTMENT OF JOINT BROKER

 

Accrol Group, the UK's leading independent tissue converter, is pleased to announce the appointment of Shore Capital Stockbrokers as Joint Broker, to work alongside Zeus, the Company's Nominated Adviser and Joint Broker, with immediate effect.

 

For further information, please contact:

 

 


Accrol Group Holdings plc


Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

Richard Newman, Chief Financial Officer


 


Zeus (Nominated Adviser & Joint Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King

Tel: +44 (0) 203 829 5000



Shore Capital Stockbrokers (Joint Broker)

Tel: +44 (0) 20 7408 4090

Malachy McEntyre / Mark Percy / James Thomas




Belvedere Communications Limited


Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525


accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls, facial tissues, and wet wipes to many of the UK's leading discounters and grocery retailers across the UK. The Group now operates from six manufacturing sites, including four in Lancashire, which together supply c.21.5% (volume) of the UK tissue market valued at c£2.5bn at retail sales value.

 

For more information, please visit www.accrol.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPDQLFBXXLBBBX
UK 100